Collaborative Agreements (Details)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
11 Months Ended |
12 Months Ended |
|
|
|
|
|
Jun. 18, 2024
USD ($)
|
May 23, 2024
USD ($)
$ / shares
shares
|
May 14, 2024
USD ($)
$ / shares
shares
|
May 08, 2024
USD ($)
$ / shares
shares
|
Apr. 16, 2024
USD ($)
$ / shares
shares
|
Mar. 25, 2024
USD ($)
$ / shares
shares
|
Jun. 10, 2022
USD ($)
|
Aug. 05, 2019
USD ($)
shares
|
Jun. 30, 2019
USD ($)
shares
|
Dec. 24, 2018
USD ($)
$ / shares
shares
|
Sep. 30, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
Sep. 25, 2017
USD ($)
|
Aug. 15, 2017
USD ($)
|
Aug. 31, 2016
USD ($)
|
Aug. 31, 2016
TWD ($)
|
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2024
USD ($)
shares
|
Dec. 31, 2022
USD ($)
|
Dec. 31, 2015
TWD ($)
|
Mar. 31, 2025 |
Jun. 30, 2024
USD ($)
|
Jul. 27, 2021
USD ($)
|
Dec. 24, 2018
$ / shares
shares
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.00%
|
|
|
|
|
|
|
|
| Total cash (in New Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000,000
|
|
|
|
|
| Cash equivalent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,600,000
|
|
|
|
|
|
|
|
| Additional paid-in capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 78,029,455
|
|
|
| Value of new shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,038,750
|
$ 2,038,750
|
|
|
|
|
|
|
|
|
| Equity method long term investment (in Shares) | shares |
|
|
|
|
|
|
|
|
|
1,530,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,530,000
|
| Service agreement eligibility amount |
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone regulatory payment amount period |
|
|
|
|
|
|
3 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loan amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 249,975
|
|
| Percentage of working capital convertible loan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
| Fixed conversion price equal (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
$ 1
|
|
|
|
|
|
|
|
|
| Licensing fee |
|
|
|
|
|
$ 33,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,895,556
|
|
|
|
|
|
| FEYE stock (in Dollars per share) | $ / shares |
|
|
|
|
|
$ 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone regulatory payment amount |
$ 3,500,000
|
|
|
|
|
$ 3,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of royalties of net sales |
|
|
|
|
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recognized revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 296,000
|
|
|
|
|
|
|
| Recognized revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
|
|
|
|
|
| Number of shares received (in Shares) | shares |
|
1.25
|
1,250,000
|
1,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,250,000
|
|
|
|
|
|
|
| BHK Co-Development Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Description of collaborative agreements |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:
●
Upon signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment
●
Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment
●
At the completion of first phase II clinical trial: $1 million, or 10% of total payment
●
At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment
●
Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment
|
|
|
|
|
|
|
|
|
| Non-refundable upfront cash payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
| Data and development percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
| Total cash amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
| Licensing rights |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 31,649,000
|
|
|
|
|
|
|
|
|
|
|
| Co-Dev Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Data and development percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
| Cash amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Addition cash payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
| Additional paid-in capital |
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash received |
|
|
|
|
|
|
|
|
|
|
|
450,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Data and development percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
|
|
|
|
| Total cash amount |
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Licensing rights |
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
| Research and development expense |
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BioFirst Corporation Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued (in Shares) | shares |
|
|
|
|
|
|
|
41,470
|
42,857
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock consideration |
|
|
|
|
|
|
|
$ 2,902,911
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ForSeeCon Eye Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Licensing agreement |
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BioLite Taiwan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total cash (in New Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000,000
|
|
|
|
|
| Cash equivalent |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,600,000
|
|
|
|
|
|
|
|
| Net sales profit, percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50.00%
|
|
|
|
|
| Collaborative agreement with ForSeeCon Eye Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront payment |
|
|
|
|
|
$ 30,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares paid (in Shares) | shares |
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares received (in Shares) | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000,000
|
5,000,000
|
|
|
|
|
|
|
|
|
| OncoX BiopPharma, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Royalty percentage |
|
5.00%
|
5.00%
|
5.00%
|
5.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | $ / shares |
|
$ 5
|
$ 5
|
$ 5
|
$ 5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued (in Shares) | shares |
|
1,250,000
|
1,250,000
|
1,250,000
|
1,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consideration paid |
|
$ 6,250,000
|
$ 6,250,000
|
$ 6,250,000
|
$ 6,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional milestone payment in cash |
|
$ 625,000
|
$ 625,000
|
$ 625,000
|
$ 625,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of develop and commercialize |
|
50.00%
|
50.00%
|
50.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Licensing fees |
|
$ 100,000
|
$ 100,000
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rgene Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Value of new shares issued |
|
|
|
|
|
|
|
|
|
$ 2,550,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of note fully converted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.65%
|
|
|
37.00%
|
|
|
|
| Loan amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
| Convertible loan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 500,000
|
$ 500,000
|
|
|
|
|
|
|
|
|
| Rgene Corporation [Member] | Co-Dev Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of note fully converted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.40%
|
6.40%
|
|
|
|
|
|
|
|
|
| Rgene Corporation [Member] | Service Agreements [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of note fully converted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.65%
|
26.65%
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Value of new shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,567
|
$ 2,567
|
|
|
|
|
|
|
|
|
| Price per share | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 50
|
| Common Stock [Member] | YuanGene Corporation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Price per share | $ / shares |
|
|
|
|
|
|
|
|
|
$ 1.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Rgene Studies [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Collaborative Agreements [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of note fully converted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20.00%
|
20.00%
|
|
|
|
|
|
|
|
|